This company seems to have been delisted
Reason: Rebranded as Talphera
Last recorded trade on: March 13, 2024
Source: https://www.fiercepharma.com/marketing/acelrx-becomes-talphera-adopting-new-name-reflect-pain-pivot
Reason: Rebranded as Talphera
Last recorded trade on: March 13, 2024
Source: https://www.fiercepharma.com/marketing/acelrx-becomes-talphera-adopting-new-name-reflect-pain-pivot
AcelRx Pharmaceuticals
ACRX
S$1.10
Share price
7.50%
Change (1 day)
34.56%
Change (1 year)
Categories
Earnings for AcelRx Pharmaceuticals (ACRX)
Earnings in 2023 (TTM): -S$13.79 Million
According to AcelRx Pharmaceuticals 's latest financial reports the company's current earnings are S$0.65 Million. In 2022 the company made an earning of S$73.7 Million, an increase over its 2021 earnings that were of -S$44.92 Million. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for AcelRx Pharmaceuticals from 2010 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2023 (TTM)  | -S$13.79 Million | -118.71% |
| 2022 | S$73.7 M | -264.1% |
| 2021 | -S$44.92 Million | -13.08% |
| 2020 | -S$51.68 Million | -24.16% |
| 2019 | -S$68.14 Million | 12.92% |
| 2018 | -S$60.35 Million | -9.7% |
| 2017 | -S$66.83 Million | 20.88% |
| 2016 | -S$55.29 Million | 82.71% |
| 2015 | -S$30.26 Million | -29.12% |
| 2014 | -S$42.69 Million | 42.38% |
| 2013 | -S$29.99 Million | -27.33% |
| 2012 | -S$41.27 Million | 66.59% |
| 2011 | -S$24.77 Million | 70.22% |
| 2010 | -S$14.55 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Cara Therapeutics
CARA | -S$80.37 Million | 510.40% | 🇺🇸 USA |
 Recro Pharma
REPH | S$4.81 M | -136.59% | 🇺🇸 USA |